deaths from glp-1 Risk of all–cause death and pancreatic events following RA initiation in people with obesity or type 2 diabetes: observations a federated research network | Cardiovascular Diabetology RGA GLP-1 Study: Weighing the

Differences in patients underlying health may account for part of the signal

Like any medication, GLP-1 medications can have side effects

Use of the injections started increasing in 2022, followed by "a sharp increase" in 2024

Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors

Coverage for weight loss treatment and obesity medications including GLP-1 medications such as semaglutide (Wegovy) and tirzepatide (Zepbound) varies significantly across Anthem Blue Cross Blue Shield plan types and plan years

GLP-1 use has also been linked to a lower risk of developing 14 obesity-related cancers, suggesting a potential preventative effect 3